DK1482932T3 - N3-alkylerede benzimidazolderivater som MEK-inhibitorer - Google Patents

N3-alkylerede benzimidazolderivater som MEK-inhibitorer

Info

Publication number: DK1482932T3
Authority: DK; Denmark
Prior art keywords: benzimidazole derivatives; mek inhibitors; alkylated benzimidazole; alkylated; mek
Prior art date: 2002-03-13

Application number

DK03714148.8T

Other languages

English (en)

Inventor

Eli M Wallace

Joseph P Lyssikatos

Brian T Hurley

Allison L Marlow

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-13

Filing date

2003-03-13

Publication date

2010-02-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1482932(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-03-13 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2010-02-01 Application granted granted Critical

2010-02-01 Publication of DK1482932T3 publication Critical patent/DK1482932T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)

DK03714148.8T 2002-03-13 2003-03-13 N3-alkylerede benzimidazolderivater som MEK-inhibitorer DK1482932T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36400702P	2002-03-13	2002-03-13
PCT/US2003/007864 WO2003077914A1 (en)	2002-03-13	2003-03-13	N3 alkylated benzimidazole derivatives as mek inhibitors

Publications (1)

Publication Number	Publication Date
DK1482932T3 true DK1482932T3 (da)	2010-02-01

Family

ID=28041856

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK10011691.2T DK2275102T3 (da)	2002-03-13	2003-03-13	N3-alkylerede benzimidazolderivater som mek-hæmmere
DK09011389.5T DK2130537T3 (da)	2002-03-13	2003-03-13	N3-alkylerede benzimidazolderivater som MEK-inhibitorer
DK03714148.8T DK1482932T3 (da)	2002-03-13	2003-03-13	N3-alkylerede benzimidazolderivater som MEK-inhibitorer
DK15177189.6T DK3000810T3 (da)	2002-03-13	2003-03-13	N3-alkyleret benzimidazolderivat som mek-inhibitor

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK10011691.2T DK2275102T3 (da)	2002-03-13	2003-03-13	N3-alkylerede benzimidazolderivater som mek-hæmmere
DK09011389.5T DK2130537T3 (da)	2002-03-13	2003-03-13	N3-alkylerede benzimidazolderivater som MEK-inhibitorer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK15177189.6T DK3000810T3 (da)	2002-03-13	2003-03-13	N3-alkyleret benzimidazolderivat som mek-inhibitor

Country Status (36)

Country	Link
US (11)	US20030232869A1 (da)
EP (5)	EP2130536B1 (da)
JP (4)	JP4093966B2 (da)
KR (3)	KR100984613B1 (da)
CN (4)	CN101486682B (da)
AR (3)	AR038971A1 (da)
AT (1)	ATE449605T1 (da)
AU (2)	AU2003218157C1 (da)
BE (1)	BE2019C510I2 (da)
BR (1)	BR122018007328B8 (da)
CA (1)	CA2478374C (da)
CL (2)	CL2012002381A1 (da)
CY (3)	CY1109727T1 (da)
DE (1)	DE60330227D1 (da)
DK (4)	DK2275102T3 (da)
DO (4)	DOP2003000613A (da)
ES (5)	ES2335276T3 (da)
FR (1)	FR19C1014I2 (da)
HK (3)	HK1070823A1 (da)
HU (2)	HUE025767T2 (da)
IL (4)	IL163995A0 (da)
IS (4)	IS2748B (da)
LT (1)	LTC1482932I2 (da)
LU (1)	LUC00100I2 (da)
MX (1)	MXPA04008893A (da)
NL (1)	NL300974I2 (da)
NZ (1)	NZ535158A (da)
PA (1)	PA8569301A1 (da)
PL (5)	PL233177B1 (da)
PT (4)	PT2130537E (da)
SG (3)	SG2013013339A (da)
SI (4)	SI1482932T1 (da)
TW (3)	TWI343377B (da)
UA (1)	UA77765C2 (da)
WO (1)	WO2003077914A1 (da)
ZA (1)	ZA200407220B (da)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
SI1482932T1 (sl) *	2002-03-13	2010-02-26	Array Biopharma Inc	N3-alkilirani derivati benzimidazola kot inhibitorji mek
US20060084682A1 (en) *	2002-12-13	2006-04-20	Heerding Dirk A	Thrombopoietin mimetics
ATE429250T1 (de) *	2003-02-26	2009-05-15	Kowa Co	Mittel zur behandlung der allergischen kontaktdermatitis
CA2532067C (en)	2003-07-24	2010-12-21	Stephen Douglas Barrett	N-methyle-substituted benzamidazoles
US7538120B2 (en) *	2003-09-03	2009-05-26	Array Biopharma Inc.	Method of treating inflammatory diseases
US7144907B2 (en) *	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
BRPI0414581C1 (pt)	2003-09-22	2021-05-25	Mei Pharma Inc	composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
US7517994B2 (en)	2003-11-19	2009-04-14	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) *	2003-11-19	2010-06-08	Array Biopharma Inc.	Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
RS51861B2 (sr)	2003-11-19	2018-03-30	Array Biopharma Inc	Heterociklični inhibitori mek-a
KR20110137838A (ko) *	2003-11-21	2011-12-23	어레이 바이오파마 인크.	Ａｋｔ 단백질 키나제 억제제
WO2005058341A2 (en) *	2003-12-11	2005-06-30	Theravance, Inc.	Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
MX2007004781A (es)	2004-10-20	2007-05-11	Applied Research Systems	Derivados de 3-arilamino piridina.
US20070299103A1 (en) *	2004-12-01	2007-12-27	Ulrich Abel	[1,2,4]Triazolo[4,3-A]Pyridine Derivatives for the Treatment of Hyperproliferative Diseases
US7429667B2 (en)	2005-01-20	2008-09-30	Ardea Biosciences, Inc.	Phenylamino isothiazole carboxamidines as MEK inhibitors
RS52243B (en)	2005-05-18	2012-10-31	Astrazeneca Ab	HETEROCYCLIC MELT INHIBITORS AND PROCEDURES FOR THEIR USE
TWI391380B (zh) *	2005-06-23	2013-04-01	Array Biopharma Inc	製備苯并咪唑化合物之方法
EP1904061B1 (en) *	2005-06-23	2018-12-26	Array Biopharma, Inc.	SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS
US8101799B2 (en)	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2012261703B2 (en) *	2005-10-07	2015-08-13	Exelixis, Inc.	Azetidines as MEK inhibitors for the treatment of proliferative diseases
AU2013203939B2 (en) *	2005-10-07	2015-08-13	Exelixis, Inc.	Azetidines as MEK inhibitors for the treatment of proliferative diseases
CN101365676B (zh) *	2005-10-07	2013-09-11	埃克塞利希斯股份有限公司	作为用于治疗增生性疾病的mek抑制剂的吖丁啶
US7572460B2 (en) *	2005-10-25	2009-08-11	Rodrigo Rodriguez-Kabana	Hydrogen cyanamide pesticide formulations
US7968108B2 (en) *	2005-10-25	2011-06-28	Metbro Distributing L.P.	Hydrogen cyanamide pesticide formulations
WO2007071951A1 (en) *	2005-12-21	2007-06-28	Astrazeneca Ab	Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
CA2534243A1 (fr)	2006-01-25	2007-07-25	Hydro Quebec	Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
GB0601962D0 (en)	2006-01-31	2006-03-15	Ucb Sa	Therapeutic agents
US7842836B2 (en)	2006-04-11	2010-11-30	Ardea Biosciences	N-aryl-N'alkyl sulfamides as MEK inhibitors
EA016674B1 (ru) *	2006-04-18	2012-06-29	Ардеа Байосайенсиз, Инк.	Пиридон сульфонамиды и пиридон сульфамиды в качестве ингибиторов mek
UA99597C2 (ru)	2006-07-06	2012-09-10	Еррей Біофарма Інк.	Пиримидилциклопентаны как ингибиторы акт протеинкиназ
US8063050B2 (en)	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8329701B2 (en)	2006-07-06	2012-12-11	Array Biopharma Inc.	Dihydrofuro pyrimidines as AKT protein kinase inhibitors
CA2656364C (en)	2006-07-06	2014-11-25	Array Biopharma Inc.	Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8492378B2 (en)	2006-08-03	2013-07-23	Takeda Pharmaceutical Company Limited	GSK-3β inhibitor
CA2660546A1 (en) *	2006-08-21	2008-02-28	Genentech, Inc.	Aza-benzofuranyl compounds and methods of use
AU2007286807B2 (en) *	2006-08-21	2013-03-21	Genentech, Inc.	Aza-benzothiophenyl compounds and methods of use
ZA200901009B (en) *	2006-08-21	2010-05-26	Genentech Inc	Aza-benzothiophenyl compounds and methods of use
TR201900306T4 (tr)	2006-12-14	2019-02-21	Exelixis Inc	Mek inhibitörlerini kullanma yöntemleri.
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
EP2134340A1 (en) *	2007-04-13	2009-12-23	AstraZeneca AB	Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
US8509487B2 (en) *	2007-04-19	2013-08-13	Avago Technologies General Ip (Singapore) Pte. Ltd.	System and method for optically measuring a parameter of an object
US8258152B2 (en)	2007-06-12	2012-09-04	Genentech, Inc.	N-substituted azaindoles and methods of use
AU2008272832B2 (en)	2007-07-05	2014-02-20	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
ES2551352T3 (es)	2007-07-05	2015-11-18	Array Biopharma, Inc.	Pirimido ciclopentanos útiles para el tratamiento de enfermedades inflamatorias o hiperproliferativas
GB0714384D0 (en)	2007-07-23	2007-09-05	Ucb Pharma Sa	theraputic agents
AU2008313504A1 (en) *	2007-10-15	2009-04-23	Astrazeneca Ab	Combination 059
US8022057B2 (en)	2007-11-12	2011-09-20	Takeda Pharmaceutical Company Limited	MAPK/ERK kinase inhibitors
SI2222675T1 (sl)	2007-12-19	2013-12-31	Genentech, Inc.	5-anilinoimidazopiridini in postopki za uporabo
PL2231662T3 (pl)	2007-12-19	2011-11-30	Genentech Inc	8-anilinoimidazopirydyny oraz ich zastosowanie jako czynników przeciwnowotworowych i/lub przeciwzapalnych
CA2707650A1 (en)	2007-12-20	2009-07-02	F. Hoffmann-La Roche Ag	Substituted hydantoins as mek kinase inhibitors
ES2387707T3 (es)	2007-12-21	2012-09-28	Genentech, Inc.	Azaindolizinas y procedimientos de uso
NZ586720A (en) *	2008-01-09	2012-11-30	Array Biopharma Inc	Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
CA2711699A1 (en)	2008-01-09	2009-07-16	Array Biopharma Inc.	Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2240494B1 (en)	2008-01-21	2016-03-30	UCB Biopharma SPRL	Thieno-pyridine derivatives as mek inhibitors
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان
GB0811304D0 (en)	2008-06-19	2008-07-30	Ucb Pharma Sa	Therapeutic agents
WO2009157167A1 (ja)	2008-06-23	2009-12-30	パナソニック株式会社	無線通信基地局装置および参照信号割当方法
WO2010003022A1 (en)	2008-07-01	2010-01-07	Genentech, Inc.	Isoindolone derivatives as mek kinase inhibitors and methods of use
WO2010003025A1 (en)	2008-07-01	2010-01-07	Genentech, Inc.	Bicyclic heterocycles as mek kinase inhibitors
ES2560878T3 (es)	2008-08-04	2016-02-23	Merck Patent Gmbh	Compuestos novedosos de fenilamino-isonicotinamida
CN101653607B (zh) *	2008-08-19	2013-02-13	鼎泓国际投资（香港）有限公司	含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
EP2358202B1 (en) *	2008-11-03	2016-06-15	Merck Sharp & Dohme Corp.	Benzimidazole and aza-benzimidazole carboxamides
ES2399384T3 (es)	2008-11-10	2013-04-01	Bayer Schering Pharma Ag	Sulfonamido fenoxibenzamidas sustituidas
US8242260B2 (en)	2009-08-28	2012-08-14	Novartis Ag	Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
EP2491015A1 (en)	2009-10-21	2012-08-29	Bayer Pharma Aktiengesellschaft	Substituted benzosulphonamides
EP2491014A1 (en)	2009-10-21	2012-08-29	Bayer Pharma Aktiengesellschaft	Substituted halophenoxybenzamide derivatives
WO2011047795A1 (en)	2009-10-21	2011-04-28	Bayer Schering Pharma Aktiengesellschaft	Substituted benzosulphonamides
WO2011095807A1 (en)	2010-02-07	2011-08-11	Astrazeneca Ab	Combinations of mek and hh inhibitors
US9205086B2 (en)	2010-04-19	2015-12-08	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
EP2560953B1 (en)	2010-04-21	2016-01-06	Probiodrug AG	Inhibitors of glutaminyl cyclase
KR20140117684A (ko)	2010-06-25	2014-10-07	노파르티스 아게	단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
CN103221043B (zh)	2010-08-05	2016-04-06	卡斯西部储备大学	用于治疗神经元连接发育障碍的erk抑制剂
DK2624696T3 (da)	2010-10-06	2017-03-13	Glaxosmithkline Llc Corp Service Company	Benzimidazolderivater som pi3-kinaseinhibitorer
CA2816188A1 (en)	2010-10-29	2012-05-03	Marion Hitchcock	Substituted phenoxypyridines
CN102020651B (zh)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-芳基氨基吡啶酮甲酰胺mek抑制剂
CA2822638C (en)	2010-12-22	2021-02-16	Fate Therapeutics, Inc.	Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
EP2655375B1 (fr)	2010-12-23	2014-12-03	Sanofi	Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
RU2013148721A (ru)	2011-04-01	2015-05-10	Дженентек, Инк.	Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
KR20140022053A (ko)	2011-04-01	2014-02-21	제넨테크, 인크.	Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
WO2012145503A1 (en)	2011-04-21	2012-10-26	Novartis Ag	Pharmaceutical combinations
EP2714039A1 (en) *	2011-05-23	2014-04-09	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US9833439B2 (en)	2011-05-25	2017-12-05	Universite Paris Descartes	ERK inhibitors for use in treating spinal muscular atrophy
EP2734205B1 (en)	2011-07-21	2018-03-21	Tolero Pharmaceuticals, Inc.	Heterocyclic protein kinase inhibitors
BR122022000334B1 (pt) *	2011-08-01	2023-03-21	Genentech, Inc	Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
US10813630B2 (en)	2011-08-09	2020-10-27	Corquest Medical, Inc.	Closure system for atrial wall
US10307167B2 (en)	2012-12-14	2019-06-04	Corquest Medical, Inc.	Assembly and method for left atrial appendage occlusion
US10314594B2 (en)	2012-12-14	2019-06-11	Corquest Medical, Inc.	Assembly and method for left atrial appendage occlusion
WO2013066483A1 (en)	2011-08-31	2013-05-10	Novartis Ag	Synergistic combinations of pi3k- and mek-inhibitors
CN103764134A (zh)	2011-09-01	2014-04-30	诺华股份有限公司	有机化合物用于治疗努南综合征的用途
EP2570127A1 (en)	2011-09-16	2013-03-20	Sanofi	Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
JP2014530243A (ja)	2011-10-14	2014-11-17	アレイバイオファーマ、インコーポレイテッド	Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物
WO2013067162A1 (en)	2011-11-02	2013-05-10	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013067165A1 (en)	2011-11-02	2013-05-10	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en)	2011-11-14	2013-05-23	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with braf inhibitors
BR112014012539B1 (pt)	2011-11-23	2022-12-20	Medimmune, Llc	Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
WO2013082511A1 (en)	2011-12-02	2013-06-06	Genentech, Inc.	Methods for overcoming tumor resistance to vegf antagonists
JP6158833B2 (ja)	2012-01-09	2017-07-05	アローヘッドファーマシューティカルズインコーポレイテッド	ベータ−カテニン関連疾患を処置するための有機組成物
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
CN103204822B (zh)	2012-01-17	2014-12-03	上海科州药物研发有限公司	作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
GB201201332D0 (en)	2012-01-26	2012-03-14	Imp Innovations Ltd	Method
ES2641864T3 (es) *	2012-03-20	2017-11-14	Novartis Ag	Terapia de combinación de un inhibidor de MEK y un inhibidor de IGF1R
EP2836873B1 (en)	2012-04-09	2020-03-11	Switch Materials, Inc.	Switching materials, and compositions and methods for making same
JP6463673B2 (ja)	2012-05-29	2019-02-06	スイッチマテリアルズインコーポレイテッドＳｗｉｔｃｈＭａｔｅｒｉａｌｓＩｎｃ．	可変透過率層を含む光学フィルタ
BR112014029338A2 (pt)	2012-05-31	2017-06-27	Bayer Pharma AG	biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc)
AR091876A1 (es) *	2012-07-26	2015-03-04	Novartis Ag	Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
KR20190057421A (ko)	2012-08-17	2019-05-28	에프. 호프만-라 로슈 아게	코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
EP3150582A1 (en)	2012-10-02	2017-04-05	Gilead Sciences, Inc.	Inhibitors of histone demethylases
CN108948043B (zh)	2012-10-12	2021-05-04	埃克塞里艾克西斯公司	制备用于治疗癌症的化合物的新型方法
US9394257B2 (en)	2012-10-16	2016-07-19	Tolero Pharmaceuticals, Inc.	PKM2 modulators and methods for their use
RU2669391C2 (ru)	2012-10-19	2018-10-11	Новартис Аг	Получение и составление композиции, содержащей ингибитор мек
US20140142689A1 (en)	2012-11-21	2014-05-22	Didier De Canniere	Device and method of treating heart valve malfunction
UA115250C2 (uk) *	2012-11-29	2017-10-10	Новартіс Аг	Фармацевтичні комбінації
EP2934515B1 (en)	2012-12-20	2018-04-04	Novartis AG	A pharmaceutical combination comprising binimetinib
EP2752191A1 (en)	2013-01-07	2014-07-09	Sanofi	Compositions and methods using hdm2 antagonist and mek inhibitor
US20140242595A1 (en)	2013-02-22	2014-08-28	Cellular Dynamics International, Inc.	Hepatocyte production via forward programming by combined genetic and chemical engineering
US10139415B2 (en)	2013-02-27	2018-11-27	Daiichi Sankyo Company, Limited	Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
CN105263906B (zh)	2013-02-27	2018-11-23	吉利德科学公司	组蛋白脱甲基酶的抑制剂
DK2970205T3 (da)	2013-03-14	2019-07-29	Tolero Pharmaceuticals Inc	JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
CN105209073A (zh)	2013-03-21	2015-12-30	诺华股份有限公司	包含B-Raf抑制剂和第二抑制剂的组合疗法
AR097617A1 (es)	2013-09-13	2016-04-06	Actelion Pharmaceuticals Ltd	Derivados antibacterianos del 2h-indazol
WO2015041533A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	Rock in combination with mapk-pathway
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
US9566443B2 (en)	2013-11-26	2017-02-14	Corquest Medical, Inc.	System for treating heart valve malfunction including mitral regurgitation
CN105829288B (zh)	2013-12-19	2019-01-15	爱杜西亚药品有限公司	抗菌1h-吲唑及1h-吲哚衍生物
US20160340407A1 (en)	2014-01-14	2016-11-24	Dana-Farber Camcer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN104788365B (zh) *	2014-01-16	2018-08-10	上海艾力斯医药科技有限公司	异烟酰胺衍生物、其制备方法及应用
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3604499A1 (en)	2014-03-04	2020-02-05	Fate Therapeutics, Inc.	Improved reprogramming methods and cell culture platforms
AR099612A1 (es)	2014-03-04	2016-08-03	Actelion Pharmaceuticals Ltd	Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
ME03558B (me)	2014-03-14	2020-07-20	Novartis Ag	Molekuli anti-lag-3 antiтela i njihove upotrebe
CA2943824A1 (en)	2014-03-31	2015-10-08	Gilead Sciences, Inc.	Inhibitors of histone demethylases
US20170107486A1 (en)	2014-04-21	2017-04-20	Cellular Dynamics International, Inc.	Hepatocyte production via forward programming by combined genetic and chemical engineering
US9796686B2 (en)	2014-05-16	2017-10-24	Idorsia Pharmaceuticals Ltd	Antibacterial quinazoline-4(3H)-one derivatives
US10023879B2 (en)	2014-06-04	2018-07-17	Fate Therapeutics, Inc.	Minimal volume reprogramming of mononuclear cells
AR101210A1 (es)	2014-07-15	2016-11-30	Genentech Inc	Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
US9802941B2 (en)	2014-08-27	2017-10-31	Gilead Sciences, Inc.	Compounds and methods for inhibiting histone demethylases
CN107206071A (zh)	2014-09-13	2017-09-26	诺华股份有限公司	Alk抑制剂的联合疗法
EP3200775B1 (en)	2014-10-03	2019-11-20	Novartis AG	Combination therapies
EP3204516B1 (en)	2014-10-06	2023-04-26	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es)	2014-10-14	2016-06-01	Novartis Ag	Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
US10842626B2 (en)	2014-12-09	2020-11-24	Didier De Canniere	Intracardiac device to correct mitral regurgitation
WO2016100882A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Combination therapies
US9580437B2 (en)	2014-12-23	2017-02-28	Novartis Ag	Triazolopyrimidine compounds and uses thereof
WO2016123100A1 (en)	2015-01-26	2016-08-04	Fate Therapeutics, Inc.	Methods and compositions for inducing hematopoietic cell differentiation
CN105566225A (zh) *	2015-02-16	2016-05-11	苏州晶云药物科技有限公司	一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
JP2016155776A (ja) *	2015-02-24	2016-09-01	学校法人兵庫医科大学	抗腫瘍効果増強剤および抗腫瘍剤
JO3746B1 (ar)	2015-03-10	2021-01-31	Aduro Biotech Inc	تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
MX2017012295A (es)	2015-03-25	2018-01-09	Novartis Ag	Derivados formilados n-heterociclicos como inhibidores de fgfr4.
MA41866A (fr)	2015-03-31	2018-02-06	Massachusetts Gen Hospital	Molécules à auto-assemblage pour l'administration ciblée de médicaments
EP3316902A1 (en)	2015-07-29	2018-05-09	Novartis AG	Combination therapies comprising antibody molecules to tim-3
EP3317301B1 (en)	2015-07-29	2021-04-07	Novartis AG	Combination therapies comprising antibody molecules to lag-3
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
AR105646A1 (es)	2015-08-11	2017-10-25	Actelion Pharmaceuticals Ltd	Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
WO2017033113A1 (en)	2015-08-21	2017-03-02	Acerta Pharma B.V.	Therapeutic combinations of a mek inhibitor and a btk inhibitor
JP2018528206A (ja)	2015-08-28	2018-09-27	ノバルティスアーゲー	Ｍｄｍ２阻害剤およびその組み合わせ物
AR105889A1 (es)	2015-09-03	2017-11-22	Actelion Pharmaceuticals Ltd	Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
SG11201802957PA (en)	2015-10-16	2018-05-30	Fate Therapeutics Inc	Platform for the induction & maintenance of ground state pluripotency
CA3004138A1 (en)	2015-11-03	2017-05-11	Janssen Biotech, Inc.	Antibodies specifically binding pd-1 and tim-3 and their uses
WO2017078807A1 (en)	2015-11-04	2017-05-11	Fate Therapeutics, Inc.	Methods and compositions for inducing hematopoietic cell differentiation
SG11201803144WA (en)	2015-11-04	2018-05-30	Fate Therapeutics Inc	Genomic engineering of pluripotent cells
US20180371093A1 (en)	2015-12-17	2018-12-27	Novartis Ag	Antibody molecules to pd-1 and uses thereof
JP2019502725A (ja)	2016-01-20	2019-01-31	フェイトセラピューティクス，インコーポレイテッド	養子免疫療法における免疫細胞調節のための組成物および方法
JP7616817B2 (ja)	2016-01-20	2025-01-17	フェイトセラピューティクス，インコーポレイテッド	養子免疫療法における免疫細胞調節のための組成物および方法
KR20220110859A (ko)	2016-03-04	2022-08-09	다이호야쿠힌고교 가부시키가이샤	악성 종양 치료용 제제 및 조성물
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
AR108257A1 (es)	2016-05-02	2018-08-01	Mei Pharma Inc	Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
SI3463345T1 (sl)	2016-06-03	2023-02-28	Array Biopharma Inc.	Farmacevtski sestavki
JP2019522049A (ja)	2016-06-20	2019-08-08	ノバルティスアーゲー	トリアゾロピリジン化合物及びその使用
KR102519922B1 (ko)	2016-06-20	2023-04-11	노파르티스 아게	트리아졸로피리미딘 화합물의 결정질 형태
JP2019524872A (ja)	2016-06-20	2019-09-05	ノバルティスアーゲー	癌の治療に有用なイミダゾピリミジン化合物
US11098077B2 (en)	2016-07-05	2021-08-24	Chinook Therapeutics, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018065924A1 (en) *	2016-10-04	2018-04-12	Sun Pharmaceutical Industries Limited	Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
WO2018092064A1 (en)	2016-11-18	2018-05-24	Novartis Ag	Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN108084078B (zh) *	2016-11-24	2021-07-30	中山大学	一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
US11932870B2 (en)	2016-12-05	2024-03-19	Fate Therapeutics, Inc.	Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3372624A1 (en)	2017-03-06	2018-09-12	Henkel AG & Co. KGaA	One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2019096112A1 (zh) *	2017-11-14	2019-05-23	深圳市塔吉瑞生物医药有限公司	一种取代的苯并咪唑化合物及包含该化合物的组合物
TW201922291A (zh)	2017-11-16	2019-06-16	瑞士商諾華公司	組合療法
TW201938165A (zh)	2017-12-18	2019-10-01	美商輝瑞股份有限公司	治療癌症的方法及組合療法
SG11202008435SA (en)	2018-03-19	2020-10-29	Taiho Pharmaceutical Co Ltd	Pharmaceutical composition including sodium alkyl sulfate
MX2020010437A (es)	2018-04-05	2021-01-29	Sumitomo Pharma Oncology Inc	Inhibidores de axl cinasa y uso de los mismos.
CN112513085B (zh)	2018-05-24	2024-06-18	詹森生物科技公司	Psma结合剂及其用途
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
CA3153630A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications Sa	Stable, concentrated radionuclide complex solutions
CA3103995A1 (en)	2018-07-26	2020-01-30	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
FI3837256T3 (fi)	2018-08-17	2023-05-15	Novartis Ag	Ureayhdisteitä ja koostumuksia smarca2/brm-atpaasiestäjinä
JP7358484B2 (ja)	2018-09-25	2023-10-10	アドヴァンスド・アクセラレーター・アプリケーションズ・（イタリー）・エッセエッレエッレ	併用療法
JP7406264B2 (ja)	2018-11-20	2023-12-27	エヌフレクションセラピューティクスインコーポレイテッド	皮膚障害の処置のためのシアノアリール－アニリン化合物
MX2021007392A (es)	2018-12-20	2021-08-24	Novartis Ag	Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
JPWO2020130125A1 (ja)	2018-12-21	2021-11-04	第一三共株式会社	抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
EP3924351A4 (en)	2019-02-12	2022-12-21	Sumitomo Pharma Oncology, Inc.	Formulations comprising heterocyclic protein kinase inhibitors
EA202192029A1 (ru)	2019-02-15	2021-10-27	Новартис Аг	Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
MX2021009763A (es)	2019-02-15	2021-09-08	Novartis Ag	Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
JP2022526713A (ja)	2019-03-21	2022-05-26	オンクセオ	がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
US11712433B2 (en)	2019-03-22	2023-08-01	Sumitomo Pharma Oncology, Inc.	Compositions comprising PKM2 modulators and methods of treatment using the same
WO2020212832A1 (en) *	2019-04-16	2020-10-22	Alembic Pharmaceuticals Limited	Process of preparation of benzimidazole compounds
MA55717A (fr)	2019-04-19	2022-02-23	Janssen Biotech Inc	Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
TWI817018B (zh)	2019-06-28	2023-10-01	美商艾瑞生藥股份有限公司	用於治療ｂｒａｆ相關的疾病和失調症之化合物
KR20220028075A (ko)	2019-07-03	2022-03-08	스미토모 다이니폰 파마 온콜로지, 인크.	티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
CA3150284A1 (en)	2019-09-26	2021-04-01	Novartis Ag	Aza-quinoline compounds and uses thereof
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021116901A1 (en) *	2019-12-09	2021-06-17	Biocon Limited	Forms of binimetinib and process for preparation thereof
CA3165399A1 (en)	2019-12-20	2021-06-24	Novartis Ag	Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US20230158152A1 (en) *	2020-03-17	2023-05-25	Medshine Discovery Inc.	Proteolysis regulator and method for using same
TW202200146A (zh)	2020-04-10	2022-01-01	日商大鵬藥品工業股份有限公司	使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
AU2021289163B2 (en)	2020-06-09	2024-05-02	Array Biopharma Inc.	4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders
IL298262A (en)	2020-06-23	2023-01-01	Novartis Ag	Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
AR123185A1 (es)	2020-08-10	2022-11-09	Novartis Ag	Compuestos y composiciones para inhibir ezh2
WO2022043556A1 (en)	2020-08-31	2022-03-03	Novartis Ag	Stable radiopharmaceutical composition
EP4204021A1 (en)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Method of treating psma-expressing cancers
US20230338587A1 (en)	2020-08-31	2023-10-26	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
EP4225307A1 (en)	2020-10-05	2023-08-16	Pierre Fabre Medicament	Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
CN112759552A (zh) *	2020-12-31	2021-05-07	武汉九州钰民医药科技有限公司	司美替尼的合成方法
CN112679438A (zh) *	2020-12-31	2021-04-20	武汉九州钰民医药科技有限公司	制备司美替尼的方法
US12141240B2 (en)	2021-01-20	2024-11-12	Rutgers, The State University Of New Jersey	Method of calibration using master calibration function
US20240228480A1 (en) *	2021-01-21	2024-07-11	Nflection Therapeutics, Inc.	Processes for preparing pyrrolopyridine-aniline compounds
AU2022214491A1 (en)	2021-01-28	2023-09-14	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
CA3206906A1 (en)	2021-02-02	2022-08-11	Andras Herner	Selective bcl-xl protac compounds and methods of use
JP2024511373A (ja)	2021-03-18	2024-03-13	ノバルティスアーゲー	がんのためのバイオマーカーおよびその使用
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
KR20230170039A (ko)	2021-04-13	2023-12-18	뉴베일런트, 아이엔씨.	Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
US20240207257A1 (en) *	2021-04-15	2024-06-27	Ideaya Biosciences, Inc.	Combination therapy comprising a pkc inhibitor and a mek inhibitor
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
CN117642166A (zh)	2021-06-09	2024-03-01	中外制药株式会社	用于癌症治疗的组合疗法
CN115490640B (zh) *	2021-06-17	2024-11-26	深圳市塔吉瑞生物医药有限公司	取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
MX2024000313A (es)	2021-07-09	2024-03-06	Plexium Inc	Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.
KR20240105382A (ko)	2021-11-04	2024-07-05	에프. 호프만-라 로슈 아게	암 치료를 위한 퀴나졸리논 화합물의 신규한 용도
WO2023084489A1 (en)	2021-11-15	2023-05-19	Pfizer Inc.	Methods of treating coronavirus disease 2019
TW202342018A (zh)	2022-03-04	2023-11-01	美商奇奈特生物製藥公司	Mek激酶抑制劑
IL317102A (en)	2022-05-20	2025-01-01	Novartis Ag	EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of using them
AR129382A1 (es)	2022-05-20	2024-08-21	Novartis Ag	Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso
WO2023238000A1 (en) *	2022-06-06	2023-12-14	Glenmark Life Sciences Limited	Process for preparation of selumetinib and salts thereof
WO2024105144A1 (en)	2022-11-18	2024-05-23	F. Hoffmann-La Roche Ag	Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
WO2024189481A1 (en)	2023-03-10	2024-09-19	Novartis Ag	Panras inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1980001113A1 (en)	1978-11-20	1980-05-29	Braun Ag	Time-keeper in particular quartz controlled clock
GB8607683D0 (en)	1986-03-27	1986-04-30	Ici Plc	Anti-tumor agents
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
IL95975A (en)	1989-10-24	1997-06-10	Takeda Chemical Industries Ltd	N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) *	1989-10-24	1993-10-05	Takeda Chemical Industries, Ltd.	Benzimidazole derivatives useful as angiotensin II inhibitors
US5218356A (en) *	1991-05-31	1993-06-08	Guenther Knapp	Wireless indoor data relay system
US5216003A (en) *	1992-01-02	1993-06-01	G. D. Searle & Co.	Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
WO1995003286A1 (fr)	1993-07-23	1995-02-02	The Green Cross Corporation	Derive de triazole et son utilisation pharmaceutique
EP0639573A1 (de)	1993-08-03	1995-02-22	Hoechst Aktiengesellschaft	Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
EP0694535A1 (en)	1994-04-29	1996-01-31	Eli Lilly And Company	Non-peptidyl tachykinin receptor antagonists
US5520187A (en) *	1994-11-25	1996-05-28	General Electric Company	Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts
US5525625A (en)	1995-01-24	1996-06-11	Warner-Lambert Company	2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
WO1996033172A1 (en)	1995-04-20	1996-10-24	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
US5972980A (en) *	1995-10-05	1999-10-26	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
PT780386E (pt)	1995-12-20	2003-02-28	Hoffmann La Roche	Inibidores de metaloprotease de matriz
GB9600344D0 (en) *	1996-01-09	1996-03-13	Lilly Co Eli	Benzimidzolyl neuropeptide y receptor antagonists
EP0923585B1 (en)	1996-07-18	2002-05-08	Pfizer Inc.	Phosphinate based inhibitors of matrix metalloproteases
PL331895A1 (en)	1996-08-23	1999-08-16	Pfizer	Arylosulphonylamino derivatives of hydroxamic acid
EP0950059B1 (en)	1997-01-06	2004-08-04	Pfizer Inc.	Cyclic sulfone derivatives
NZ336840A (en)	1997-02-03	2001-01-26	Pfizer Prod Inc	Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
WO1998034915A1 (en)	1997-02-07	1998-08-13	Pfizer Inc.	N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
ID22809A (id)	1997-02-11	1999-12-09	Pfizer	Turunan-turunan asam arilsulfonil hidroksamat
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6821963B2 (en) *	1997-07-01	2004-11-23	Warner-Lambert Company	4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) *	1997-07-01	2003-01-14	Warner-Lambert Company	4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6310060B1 (en)	1998-06-24	2001-10-30	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
AU756586C (en)	1997-07-01	2004-01-29	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
CN1163475C (zh)	1997-07-01	2004-08-25	沃尼尔·朗伯公司	4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
US6534503B1 (en) *	1998-04-28	2003-03-18	Lion Bioscience Ag	Melanocortin receptor-3 ligands to treat sexual dysfunction
AUPP616498A0 (en)	1998-09-25	1998-10-15	University Of Queensland, The	Synthesis of cyclic peptides
BR9916785A (pt)	1999-01-07	2001-10-23	Warner Lambert Co	Tratamento de asma com inibidores mek
AU2203800A (en)	1999-01-07	2000-07-24	Warner-Lambert Company	Antiviral method using mek inhibitors
CA2349832A1 (en) *	1999-01-13	2000-07-20	Warner-Lambert Company	Benzenesulfonamide derivatives and their use as mek inhibitors
TR200102029T2 (tr)	1999-01-13	2001-11-21	Warner-Lambert Company	1-Heterosiklil ikameli diarilaminler.
DE69926800T2 (de) *	1999-01-13	2006-05-18	Warner-Lambert Company Llc	Benzoheterozyklen und ihre verwendung als mek inhibitoren
CA2349467A1 (en) *	1999-01-13	2000-07-20	Warner-Lambert Company	Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
JP2002534446A (ja)	1999-01-13	2002-10-15	ワーナー−ランバート・カンパニー	４′ヘテロアリールジアリールアミン
JP2000204077A (ja)	1999-01-13	2000-07-25	Warner Lambert Co	ジアリ―ルアミン
CA2348236A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
GB9910577D0 (en)	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
GB9912961D0 (en)	1999-06-03	1999-08-04	Pfizer Ltd	Metalloprotease inhibitors
TR200200205T2 (tr)	1999-07-16	2002-06-21	Warner-Lambert Company	MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
AU5786000A (en)	1999-07-16	2001-02-05	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
US7030119B1 (en) *	1999-07-16	2006-04-18	Warner-Lambert Company	Method for treating chronic pain using MEK inhibitors
HUP0202319A3 (en) *	1999-07-16	2004-12-28	Warner Lambert Co	Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
CN1358095A (zh)	1999-07-16	2002-07-10	沃尼尔·朗伯公司	使用mek抑制剂治疗慢性疼痛的方法
EP1214330A1 (en)	1999-09-21	2002-06-19	LION Bioscience AG	Benzimidazole derivatives and combinatorial libraries thereof
US7001905B2 (en) *	2000-03-15	2006-02-21	Warner-Lambert Company	Substituted diarylamines as MEK inhibitors
WO2001068619A1 (en)	2000-03-15	2001-09-20	Warner-Lambert Company	5-amide substituted diarylamines as mex inhibitors
YU2503A (sh) *	2000-07-19	2006-05-25	Warner-Lambert Company	Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
IL154507A0 (en)	2000-08-25	2003-09-17	Warner Lambert Co	Process for making n-aryl-anthranilic acids and their derivatives
AU2002210714A1 (en) *	2000-11-02	2002-06-11	Astrazeneca Ab	Substituted quinolines as antitumor agents
AU2002221239A1 (en) *	2000-12-07	2002-06-18	Astrazeneca Ab	Therapeutic benzimidazole compounds
US7102009B2 (en) *	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
MXPA03008143A (es) *	2001-03-09	2005-08-16	Johnson & Johnson	Compuestos heterociclicos.
US20040039208A1 (en)	2001-07-20	2004-02-26	Chen Michael Huai Gu	Process for making n-aryl-anthranilic acids and their derivatives
EP1427408A4 (en) *	2001-09-17	2005-10-26	Bristol Myers Squibb Co	CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM)
WO2003054180A1 (en)	2001-12-21	2003-07-03	Warner-Lambert Company Llc	Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
WO2003062191A1 (en)	2002-01-23	2003-07-31	Warner-Lambert Company Llc	N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
SI1482932T1 (sl)	2002-03-13	2010-02-26	Array Biopharma Inc	N3-alkilirani derivati benzimidazola kot inhibitorji mek
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
TW200406203A (en) *	2002-03-13	2004-05-01	Array Biopharma Inc	N3 alkylated banzimidazole derivatives as MEK inhibitors
DE10238002A1 (de) *	2002-08-20	2004-03-04	Merck Patent Gmbh	Benzimidazolderivate
NZ538401A (en) *	2002-09-06	2008-03-28	Janssen Pharmaceutica Nv	(1H-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders
US20040127395A1 (en) *	2002-09-06	2004-07-01	Desai Pragnya J.	Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US7582635B2 (en) *	2002-12-24	2009-09-01	Purdue Pharma, L.P.	Therapeutic agents useful for treating pain
CA2532067C (en)	2003-07-24	2010-12-21	Stephen Douglas Barrett	N-methyle-substituted benzamidazoles
DE102005032379A1 (de)	2005-07-08	2007-01-11	Conti Temic Microelectronic Gmbh	Zugangskontrollsystem für ein Kraftfahrzeug
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
EP2934515B1 (en)	2012-12-20	2018-04-04	Novartis AG	A pharmaceutical combination comprising binimetinib

2003
- 2003-03-13 SI SI200331731T patent/SI1482932T1/sl unknown
- 2003-03-13 CN CN2008101903429A patent/CN101486682B/zh not_active Expired - Lifetime
- 2003-03-13 SG SG2013013339A patent/SG2013013339A/en unknown
- 2003-03-13 ES ES03714148T patent/ES2335276T3/es not_active Expired - Lifetime
- 2003-03-13 KR KR1020107007537A patent/KR100984613B1/ko active Protection Beyond IP Right Term
- 2003-03-13 UA UA20040907722A patent/UA77765C2/uk unknown
- 2003-03-13 DO DO2003000613A patent/DOP2003000613A/es unknown
- 2003-03-13 CA CA002478374A patent/CA2478374C/en not_active Expired - Lifetime
- 2003-03-13 SI SI200332449T patent/SI2275102T1/sl unknown
- 2003-03-13 JP JP2003575967A patent/JP4093966B2/ja not_active Expired - Lifetime
- 2003-03-13 SI SI200332546T patent/SI3000810T1/sl unknown
- 2003-03-13 DK DK10011691.2T patent/DK2275102T3/da active
- 2003-03-13 IL IL16399503A patent/IL163995A0/xx unknown
- 2003-03-13 ZA ZA200407220A patent/ZA200407220B/xx unknown
- 2003-03-13 SI SI200332221T patent/SI2130537T1/sl unknown
- 2003-03-13 PT PT90113895T patent/PT2130537E/pt unknown
- 2003-03-13 NZ NZ535158A patent/NZ535158A/en not_active IP Right Cessation
- 2003-03-13 CN CNB038107546A patent/CN100519539C/zh not_active Expired - Lifetime
- 2003-03-13 CN CN2009101492905A patent/CN101633644B/zh not_active Expired - Lifetime
- 2003-03-13 PL PL401635A patent/PL233177B1/pl unknown
- 2003-03-13 AU AU2003218157A patent/AU2003218157C1/en active Active
- 2003-03-13 PL PL401636A patent/PL233493B1/pl unknown
- 2003-03-13 PL PL377628A patent/PL230179B1/pl unknown
- 2003-03-13 EP EP09011388.7A patent/EP2130536B1/en not_active Expired - Lifetime
- 2003-03-13 TW TW099113379A patent/TWI343377B/zh not_active IP Right Cessation
- 2003-03-13 TW TW092105718A patent/TWI338685B/zh not_active IP Right Cessation
- 2003-03-13 EP EP03714148A patent/EP1482932B1/en not_active Expired - Lifetime
- 2003-03-13 ES ES10011691.2T patent/ES2549159T3/es not_active Expired - Lifetime
- 2003-03-13 PT PT151771896T patent/PT3000810T/pt unknown
- 2003-03-13 EP EP10011691.2A patent/EP2275102B1/en not_active Expired - Lifetime
- 2003-03-13 PL PL401638A patent/PL401638A1/pl unknown
- 2003-03-13 PT PT03714148T patent/PT1482932E/pt unknown
- 2003-03-13 DK DK09011389.5T patent/DK2130537T3/da active
- 2003-03-13 PL PL401637A patent/PL401637A1/pl unknown
- 2003-03-13 EP EP15177189.6A patent/EP3000810B1/en not_active Revoked
- 2003-03-13 AT AT03714148T patent/ATE449605T1/de active
- 2003-03-13 ES ES15177189.6T patent/ES2635666T3/es not_active Expired - Lifetime
- 2003-03-13 WO PCT/US2003/007864 patent/WO2003077914A1/en active Application Filing
- 2003-03-13 SG SG200608672-2A patent/SG148857A1/en unknown
- 2003-03-13 PA PA20038569301A patent/PA8569301A1/es unknown
- 2003-03-13 PT PT100116912T patent/PT2275102E/pt unknown
- 2003-03-13 ES ES09011389T patent/ES2394347T3/es not_active Expired - Lifetime
- 2003-03-13 KR KR1020107007539A patent/KR100984573B1/ko active IP Right Grant
- 2003-03-13 AR ARP030100887A patent/AR038971A1/es active IP Right Grant
- 2003-03-13 ES ES09011388T patent/ES2407849T3/es not_active Expired - Lifetime
- 2003-03-13 KR KR1020047014182A patent/KR100984595B1/ko active IP Right Grant
- 2003-03-13 TW TW099113360A patent/TWI350285B/zh not_active IP Right Cessation
- 2003-03-13 CN CN200910149291XA patent/CN101633645B/zh not_active Expired - Lifetime
- 2003-03-13 DK DK03714148.8T patent/DK1482932T3/da active
- 2003-03-13 SG SG2011042850A patent/SG194238A1/en unknown
- 2003-03-13 HU HUE10011691A patent/HUE025767T2/en unknown
- 2003-03-13 MX MXPA04008893A patent/MXPA04008893A/es active IP Right Grant
- 2003-03-13 US US10/387,879 patent/US20030232869A1/en not_active Abandoned
- 2003-03-13 DK DK15177189.6T patent/DK3000810T3/da active
- 2003-03-13 DE DE60330227T patent/DE60330227D1/de not_active Expired - Lifetime
- 2003-03-13 EP EP09011389A patent/EP2130537B1/en not_active Expired - Lifetime
- 2003-12-12 BR BR122018007328A patent/BR122018007328B8/pt active IP Right Grant
2004
- 2004-09-09 IS IS7442A patent/IS2748B/is unknown
- 2004-09-09 IL IL163995A patent/IL163995A/en active IP Right Grant
2005
- 2005-02-18 US US11/061,336 patent/US7425637B2/en not_active Expired - Lifetime
- 2005-04-26 HK HK05103569.0A patent/HK1070823A1/xx not_active IP Right Cessation
2007
- 2007-10-09 JP JP2007263512A patent/JP2008019277A/ja active Pending
2008
- 2008-01-29 JP JP2008017547A patent/JP5102642B2/ja not_active Expired - Lifetime
- 2008-03-18 US US12/050,847 patent/US7576114B2/en not_active Expired - Lifetime
- 2008-03-18 US US12/050,827 patent/US7777050B2/en not_active Expired - Lifetime
2009
- 2009-10-07 AU AU2009222613A patent/AU2009222613B2/en active Active
2010
- 2010-01-13 CY CY20101100037T patent/CY1109727T1/el unknown
- 2010-03-10 IL IL204419A patent/IL204419A/en active IP Right Grant
- 2010-03-10 IL IL204420A patent/IL204420A/en active Protection Beyond IP Right Term
- 2010-06-09 HK HK10105717.9A patent/HK1141976A1/xx not_active IP Right Cessation
- 2010-06-28 US US12/824,521 patent/US8193229B2/en not_active Expired - Fee Related
- 2010-06-28 US US12/824,559 patent/US8178693B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,497 patent/US7973170B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,477 patent/US8003805B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,547 patent/US8193230B2/en not_active Expired - Fee Related
- 2010-06-29 US US12/826,158 patent/US8193231B2/en not_active Expired - Fee Related
2011
- 2011-04-20 DO DO2011000110A patent/DOP2011000110A/es unknown
- 2011-04-20 DO DO2011000109A patent/DOP2011000109A/es unknown
- 2011-06-16 IS IS8961A patent/IS2999B/is unknown
- 2011-06-16 IS IS8960A patent/IS2998B/is unknown
- 2011-06-16 IS IS8959A patent/IS2990B/is unknown
- 2011-07-13 HK HK11107302.5A patent/HK1153139A1/zh not_active IP Right Cessation
2012
- 2012-05-03 US US13/463,487 patent/US8513293B2/en not_active Expired - Lifetime
- 2012-08-24 JP JP2012184708A patent/JP5498546B2/ja not_active Expired - Lifetime
- 2012-08-29 CL CL2012002381A patent/CL2012002381A1/es unknown
- 2012-08-29 CL CL2012002380A patent/CL2012002380A1/es unknown
2013
- 2013-01-28 DO DO2013000023A patent/DOP2013000023A/es unknown
- 2013-02-25 AR ARP130100567A patent/AR090143A2/es unknown
- 2013-02-25 AR ARP130100568A patent/AR090144A2/es unknown
2017
- 2017-07-27 CY CY20171100805T patent/CY1119136T1/el unknown
2019
- 2019-02-12 LU LU00100C patent/LUC00100I2/fr unknown
- 2019-03-01 HU HUS1900011C patent/HUS1900011I1/hu unknown
- 2019-03-07 LT LTPA2019007C patent/LTC1482932I2/lt unknown
- 2019-03-12 FR FR19C1014C patent/FR19C1014I2/fr active Active
- 2019-03-13 BE BE2019C510C patent/BE2019C510I2/fr unknown
- 2019-03-15 NL NL300974C patent/NL300974I2/nl unknown
- 2019-03-18 CY CY2019012C patent/CY2019012I2/el unknown

Also Published As

Publication number	Publication date
AU2003218157C1 (en)	2011-11-24
US7576114B2 (en)	2009-08-18
SG2013013339A (en)	2014-12-30
UA77765C2 (en)	2007-01-15
WO2003077914A1 (en)	2003-09-25
US20050143438A1 (en)	2005-06-30
HK1070823A1 (en)	2005-06-30
US7425637B2 (en)	2008-09-16
AR090144A2 (es)	2014-10-22
SG148857A1 (en)	2009-01-29
PL377628A1 (pl)	2006-02-06
RU2307831C9 (ru)	2008-06-10
PL230179B1 (pl)	2018-09-28
ES2407849T3 (es)	2013-06-14
BR122018007328B1 (pt)	2020-03-03
TWI343377B (en)	2011-06-11
AU2003218157B2 (en)	2009-07-09
AU2003218157A1 (en)	2003-09-29
EP2275102B1 (en)	2015-07-29
TW201031641A (en)	2010-09-01
CN101486682A (zh)	2009-07-22
US20030232869A1 (en)	2003-12-18
TWI350285B (en)	2011-10-11
CL2012002380A1 (es)	2012-11-05
US8193230B2 (en)	2012-06-05
BR122018007328B8 (pt)	2021-05-25
IL204420A (en)	2012-12-31
SI3000810T1 (sl)	2017-10-30
MXPA04008893A (es)	2005-06-20
LTPA2019007I1 (lt)	2019-03-25
JP4093966B2 (ja)	2008-06-04
PT2130537E (pt)	2012-12-20
TW201031642A (en)	2010-09-01
CL2012002381A1 (es)	2012-11-05
ES2335276T3 (es)	2010-03-24
PT1482932E (pt)	2010-01-12
KR20100040759A (ko)	2010-04-20
KR20100040760A (ko)	2010-04-20
US8003805B2 (en)	2011-08-23
EP2130536B1 (en)	2013-05-08
ES2394347T3 (es)	2013-01-30
US20100267710A1 (en)	2010-10-21
JP2008163034A (ja)	2008-07-17
EP2275102A1 (en)	2011-01-19
AU2009222613B2 (en)	2011-06-16
PL401635A1 (pl)	2013-05-27
US20080177082A1 (en)	2008-07-24
CN101633644B (zh)	2012-05-09
EP1482932A1 (en)	2004-12-08
US20100260714A1 (en)	2010-10-14
AR038971A1 (es)	2005-02-02
IS7442A (is)	2004-09-09
US20100261718A1 (en)	2010-10-14
EP3000810A1 (en)	2016-03-30
IS8959A (is)	2011-06-16
IL204419A0 (en)	2011-07-31
ZA200407220B (en)	2007-05-30
DOP2011000109A (es)	2011-11-30
CN101633645B (zh)	2011-06-22
CN100519539C (zh)	2009-07-29
US20100267793A1 (en)	2010-10-21
PA8569301A1 (es)	2004-10-08
CY1119136T1 (el)	2018-02-14
CY2019012I1 (el)	2020-05-29
JP2008019277A (ja)	2008-01-31
PL233493B1 (pl)	2019-10-31
NZ535158A (en)	2007-06-29
SG194238A1 (en)	2013-11-29
DOP2013000023A (es)	2013-06-30
RU2307831C2 (ru)	2007-10-10
TWI338685B (en)	2011-03-11
KR100984595B1 (ko)	2010-09-30
SI2130537T1 (sl)	2013-01-31
DOP2011000110A (es)	2011-11-30
LTC1482932I2 (lt)	2020-04-27
PL233177B1 (pl)	2019-09-30
FR19C1014I1 (fr)	2019-04-19
FR19C1014I2 (fr)	2020-03-13
IL204419A (en)	2012-12-31
KR100984613B1 (ko)	2010-09-30
ATE449605T1 (de)	2009-12-15
IS8961A (is)	2011-06-16
IL204420A0 (en)	2011-07-31
JP2012224649A (ja)	2012-11-15
EP1482932A4 (en)	2006-04-05
US8178693B2 (en)	2012-05-15
ES2635666T3 (es)	2017-10-04
JP5102642B2 (ja)	2012-12-19
US7973170B2 (en)	2011-07-05
BE2019C510I2 (da)	2022-05-19
US8193231B2 (en)	2012-06-05
JP2005530709A (ja)	2005-10-13
PL401637A1 (pl)	2013-05-27
US20120277277A1 (en)	2012-11-01
PL401638A1 (pl)	2013-05-27
HK1141976A1 (en)	2010-11-26
PT3000810T (pt)	2017-10-25
HK1153139A1 (zh)	2012-03-23
EP1482932B1 (en)	2009-11-25
CN101633645A (zh)	2010-01-27
PL401636A1 (pl)	2013-05-27
US20100261717A1 (en)	2010-10-14
PT2275102E (pt)	2015-10-27
US7777050B2 (en)	2010-08-17
CA2478374A1 (en)	2003-09-25
US8513293B2 (en)	2013-08-20
IS2990B (is)	2017-12-15
HUE025767T2 (en)	2016-05-30
EP2130537B1 (en)	2012-11-14
CA2478374C (en)	2009-01-06
LUC00100I1 (da)	2019-02-13
US20110158971A1 (en)	2011-06-30
IS8960A (is)	2011-06-16
US20080171778A1 (en)	2008-07-17
KR100984573B1 (ko)	2010-09-30
CY1109727T1 (el)	2014-09-10
DK2130537T3 (da)	2013-02-18
KR20040094786A (ko)	2004-11-10
US8193229B2 (en)	2012-06-05
ES2549159T3 (es)	2015-10-23
SI2275102T1 (sl)	2015-12-31
DE60330227D1 (de)	2010-01-07
CY2019012I2 (el)	2020-05-29
SI1482932T1 (sl)	2010-02-26
NL300974I2 (nl)	2022-04-06
IS2748B (is)	2011-08-15
DOP2003000613A (es)	2003-09-30
IS2998B (is)	2018-06-15
DK3000810T3 (da)	2017-10-16
CN101486682B (zh)	2013-08-14
TW200407129A (en)	2004-05-16
DK2275102T3 (da)	2015-11-02
EP2130536A1 (en)	2009-12-09
JP5498546B2 (ja)	2014-05-21
LUC00100I2 (da)	2020-01-23
AR090143A2 (es)	2014-10-22
CN101633644A (zh)	2010-01-27
CN1652776A (zh)	2005-08-10
IL163995A (en)	2010-11-30
EP3000810B1 (en)	2017-07-19
IL163995A0 (en)	2005-12-18
AU2009222613A1 (en)	2009-10-29
HUS1900011I1 (hu)	2019-04-29
EP2130537A1 (en)	2009-12-09
RU2004127926A (ru)	2005-06-27
IS2999B (is)	2018-06-15

Publication	Publication Date	Title
DK2130537T3 (da)	2013-02-18	N3-alkylerede benzimidazolderivater som MEK-inhibitorer
DK1492785T3 (da)	2009-03-02	2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
IS7667A (is)	2005-01-27	Nýjar bensimídazólafleiður
IS8384A (is)	2006-03-29	Alkýleraðar bensímídasólafleiður sem MEK-hindrar
CY2016042I1 (el)	2017-03-15	Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO20044654L (no)	2004-10-28	Piperidinoylpiperidiner som 5-HTIF-agonister
DK1663232T3 (da)	2008-02-04	Benzimidazolderivater som human chymase-inhibitorer
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
NO20052887D0 (no)	2005-06-14	Pyridazinonderivater som GSK-3Beta inhibitorer.
DK1585749T3 (da)	2008-09-22	Diazepinoindol-derivater som kinaseinhibitorer
NO20043793L (no)	2004-10-21	Nikotinamidderivater anvendelige som PDE4 inhibitorer
NO20055680D0 (no)	2005-12-01	Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20050665L (no)	2005-04-18	Pyrrolidonderivater som MAOE inhibitoere
DK1542977T3 (da)	2007-03-19	2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12
DK1797042T3 (da)	2009-03-02	Indozolonderivater som 11B-HSD1-inhibitorer
DE60320933D1 (de)	2008-06-26	Rho-kinase inhibitoren
DK1603570T3 (da)	2013-05-21	Aminoheteroarylforbindelser som proteinkinaseinhibitorer
ATE386518T1 (de)	2008-03-15	Benzimidazolderivate
DK1499316T3 (da)	2008-07-21	(1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
NO20044998L (no)	2005-01-18	Tioksantinderivater som myeloperoksidaseinhibitorer
NO20051236L (no)	2005-04-08	Heterobiarylderivater som matriksmetalloproteinaseinhibitorer
DK1311488T3 (da)	2010-01-04	Substituerede imidazoler som tafia-inhibitorer
DK1740569T3 (da)	2008-06-02	Imidazol-derivater som TAFla-inhibitorer
DK1511718T3 (da)	2009-06-22	N-acylaminobenzenderivater som selektive monoaminoxidase B-inhibitorer
ATE308325T1 (de)	2005-11-15	Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren